Molecule Information

General Information of the Molecule (ID: Mol00844)

• Name: Beta-lactamase (BLA) ,Salmonella enterica serotype wien
• Synonyms: bla_SHV-12
• Molecule Type: Protein
• Gene Name: blaSHV-12
• Sequence:
  MRYIRLCIISLLATLPLAVHASPQPLEQIKQSESQLSGRVGMIEMDLASGRTLTAWRADE
  RFPMMSTFKVVLCGAVLARVDAGDEQLERKIHYRQQDLVDYSPVSEKHLADGMTVGELCA
  AAITMSDNSAANLLLATVGGPAGLTAFLRQIGDNVTRLDRWETELNEALPGDARDTTTPA
  SMAATLRKLLTSQRLSARSQRQLLQWMVDDRVAGPLIRSVLPAGWFIADKTGASKRGARG
  IVALLGPNNKAERIVVIYLRDTPASMAERNQQIAGIGAALIEHWQR
• Uniprot ID: B1NX62_SALET

Kingdom: N.A.
Phylum: Proteobacteria
Class: Gammaproteobacteria
Order: Enterobacterales
Family: Enterobacteriaceae
Genus: Salmonella
Species: Salmonella enterica subsp. enterica serovar Braenderup

Type(s) of Resistant Mechanism of This Molecule

  DISM: Drug Inactivation by Structure Modification

Drug Resistance Data Categorized by Drug

Approved Drug(s) 2 drug(s) in total

Ceftazidime

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Drug Inactivation by Structure Modification (DISM)

Disease Class: Salmonella enterica infection [1]

• Resistant Disease: Salmonella enterica infection [ICD-11: 1A09.0]
• Resistant Drug: Ceftazidime
• Molecule Alteration: Expression; Inherence
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: Enterobacter cloacae strains ENLA-1; 550
• In Vitro Model: Escherichia coli strain ECAA-1; 562
• In Vitro Model: Escherichia coli strain ECLA-1; 562
• In Vitro Model: Escherichia coli strain ECLA-2; 562
• In Vitro Model: Escherichia coli strain ECLA-4; 562
• In Vitro Model: Escherichia coli strain ECZK-1; 562
• In Vitro Model: Escherichia coli strain ECZP-1; 562
• In Vitro Model: Escherichia coli strain ECZU-1; 562
• In Vitro Model: Escherichia coli strain HK225f; 562
• In Vitro Model: Salmonella enterica serotype wien strain SWLA-1; 149384
• In Vitro Model: Salmonella enterica serotype wien strain SWLA-2; 149384
• In Vitro Model: Klebsiella pneumoniae strains kPAA-1; 573
• In Vitro Model: Klebsiella pneumoniae strains kPBE-2; 573
• In Vitro Model: Klebsiella pneumoniae strains kPGE-1; 573
• In Vitro Model: Klebsiella pneumoniae strains kPGE-2; 573
• In Vitro Model: Klebsiella pneumoniae strains kPLA-1; 573
• In Vitro Model: Klebsiella pneumoniae strains kPLA-10; 573
• In Vitro Model: Klebsiella pneumoniae strains kPLA-2; 573
• In Vitro Model: Klebsiella pneumoniae strains kPLA-3; 573
• In Vitro Model: Klebsiella pneumoniae strains kPLA-4; 573
• In Vitro Model: Klebsiella pneumoniae strains kPLA-5; 573
• In Vitro Model: Klebsiella pneumoniae strains kPLA-6; 573
• In Vitro Model: Klebsiella pneumoniae strains kPLA-7; 573
• In Vitro Model: Klebsiella pneumoniae strains kPLA-8; 573
• In Vitro Model: Klebsiella pneumoniae strains kPLA-9; 573
• In Vitro Model: Klebsiella pneumoniae strains kPZU-1; 573
• In Vitro Model: Klebsiella pneumoniae strains kPZU-10; 573
• In Vitro Model: Klebsiella pneumoniae strains kPZU-11; 573
• In Vitro Model: Klebsiella pneumoniae strains kPZU-12; 573
• In Vitro Model: Klebsiella pneumoniae strains kPZU-13; 573
• In Vitro Model: Klebsiella pneumoniae strains kPZU-4; 573
• In Vitro Model: Klebsiella pneumoniae strains kPZU-6; 573
• In Vitro Model: Klebsiella pneumoniae strains kPZU-7; 573
• In Vitro Model: Klebsiella pneumoniae strains kPZU-8; 573
• In Vitro Model: Klebsiella pneumoniae strains kPZU-9; 573
• Experiment for Molecule Alteration: Hybridization experiments assay
• Experiment for Drug Resistance: Microdilution method assay
• Mechanism Description: Of 60 strains with reduced susceptibility to expanded-spectrum cephalosporins which had been collected, 34 (24Klebsiella pneumoniae, 7Escherichia coli, 1Enterobacter cloacae, and 2Salmonella entericaserotypewien) hybridized with the intragenic blaSHVprobe. TheblaSHVgenes were amplified by PCR, and the presence ofblaSHV-ESBLwas established in 29 strains by restriction enzyme digests of the resulting 1,018-bp amplimers as described elsewhere. These results were confirmed by the nucleotide sequencing of all 34 amplimers. Five strains contained SHV non-ESBL enzymes.

Ceftriaxone

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Drug Inactivation by Structure Modification (DISM)

Disease Class: Salmonella enterica infection [1]

• Resistant Disease: Salmonella enterica infection [ICD-11: 1A09.0]
• Resistant Drug: Ceftriaxone
• Molecule Alteration: Expression; Inherence
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: Enterobacter cloacae strains ENLA-1; 550
• In Vitro Model: Escherichia coli strain ECAA-1; 562
• In Vitro Model: Escherichia coli strain ECLA-1; 562
• In Vitro Model: Escherichia coli strain ECLA-2; 562
• In Vitro Model: Escherichia coli strain ECLA-4; 562
• In Vitro Model: Escherichia coli strain ECZK-1; 562
• In Vitro Model: Escherichia coli strain ECZP-1; 562
• In Vitro Model: Escherichia coli strain ECZU-1; 562
• In Vitro Model: Escherichia coli strain HK225f; 562
• In Vitro Model: Salmonella enterica serotype wien strain SWLA-1; 149384
• In Vitro Model: Salmonella enterica serotype wien strain SWLA-2; 149384
• In Vitro Model: Klebsiella pneumoniae strains kPAA-1; 573
• In Vitro Model: Klebsiella pneumoniae strains kPBE-2; 573
• In Vitro Model: Klebsiella pneumoniae strains kPGE-1; 573
• In Vitro Model: Klebsiella pneumoniae strains kPGE-2; 573
• In Vitro Model: Klebsiella pneumoniae strains kPLA-1; 573
• In Vitro Model: Klebsiella pneumoniae strains kPLA-10; 573
• In Vitro Model: Klebsiella pneumoniae strains kPLA-2; 573
• In Vitro Model: Klebsiella pneumoniae strains kPLA-3; 573
• In Vitro Model: Klebsiella pneumoniae strains kPLA-4; 573
• In Vitro Model: Klebsiella pneumoniae strains kPLA-5; 573
• In Vitro Model: Klebsiella pneumoniae strains kPLA-6; 573
• In Vitro Model: Klebsiella pneumoniae strains kPLA-7; 573
• In Vitro Model: Klebsiella pneumoniae strains kPLA-8; 573
• In Vitro Model: Klebsiella pneumoniae strains kPLA-9; 573
• In Vitro Model: Klebsiella pneumoniae strains kPZU-1; 573
• In Vitro Model: Klebsiella pneumoniae strains kPZU-10; 573
• In Vitro Model: Klebsiella pneumoniae strains kPZU-11; 573
• In Vitro Model: Klebsiella pneumoniae strains kPZU-12; 573
• In Vitro Model: Klebsiella pneumoniae strains kPZU-13; 573
• In Vitro Model: Klebsiella pneumoniae strains kPZU-4; 573
• In Vitro Model: Klebsiella pneumoniae strains kPZU-6; 573
• In Vitro Model: Klebsiella pneumoniae strains kPZU-7; 573
• In Vitro Model: Klebsiella pneumoniae strains kPZU-8; 573
• In Vitro Model: Klebsiella pneumoniae strains kPZU-9; 573
• Experiment for Molecule Alteration: Hybridization experiments assay
• Experiment for Drug Resistance: Microdilution method assay
• Mechanism Description: Of 60 strains with reduced susceptibility to expanded-spectrum cephalosporins which had been collected, 34 (24Klebsiella pneumoniae, 7Escherichia coli, 1Enterobacter cloacae, and 2Salmonella entericaserotypewien) hybridized with the intragenic blaSHVprobe. TheblaSHVgenes were amplified by PCR, and the presence ofblaSHV-ESBLwas established in 29 strains by restriction enzyme digests of the resulting 1,018-bp amplimers as described elsewhere. These results were confirmed by the nucleotide sequencing of all 34 amplimers. Five strains contained SHV non-ESBL enzymes.

References

• Ref 1: Survey and molecular genetics of SHV beta-lactamases in Enterobacteriaceae in Switzerland: two novel enzymes, SHV-11 and SHV-12. Antimicrob Agents Chemother. 1997 May;41(5):943-9. doi: 10.1128/AAC.41.5.943.